FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/11/2023
Voltar para busca
Dado oficial do USPTO
RIKEN-NKT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
12/11/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 44
Data de depósito
30/07/2021
Data de registro
27/06/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/06/2023
Última transação
27/06/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
JP
Examinador
HUDSON, TAMARA
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "RIKEN-NKT" in stylized orange font, with the letter "R" forming an orange infinity symbol to the upper left of the letter; the color white in the mark indicates background and is not claimed as a feature of the mark.
Titulares e representantes
Titulares
RIKEN IMMUNE REGENERATIVE MEDICINE INC.
Representantes
M. Scott Alprin Alprin Law Offices, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Cells for medical use or clinical use; cells for medical use or clinical use for treatment or prevention of cancer; cells as pharmaceutical for treatment or prevention of cancer; biological preparations for use in cell cultures for medical purposes for the treatment of cancerimmune diseaseallergic diseasediabetesmyasthenia including lambert-Eaton syndromeParkinson's diseaserenal failuredementia; cellular function activating agents for medical purposes; pharmaceutical preparations for activating cellular function; pharmaceutical preparationsother than agrochemicalsfor the treatment of cancerimmune diseaseallergic diseasediabetesmyasthenia including lambert-Eaton syndromeParkinson's diseaserenal failuredementia; reagent paper for medical purposes; nutritional supplements; dietetic preparations adapted for medical purposes
Classe 44
Medical treatment services utilizing cell growth or cell activation and consultancy and information services relating thereof; medical treatment or prevention of cancer utilizing cell growth or cell activation and consultancy and information services relating thereof; providing medical cancer treatment and consultancy and information services relating thereof; medical servicesproviding clinical examinations related to medical treatment and consultancy and information services relating thereof; medical servicesproviding clinical examinations and medication thereof as well as consultancy and information services relating thereof; medical treatment services and consultancy and information services relating thereof; medical check-up services and consultancy and information services relating thereof; dental care services; provision of pharmaceutical information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
29/09/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
29/09/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/09/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/06/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
27/06/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/05/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
17/05/2023
GPNX
NOTIFICATION PROCESSED BY IB
13/04/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/04/2023
PUBO
PUBLISHED FOR OPPOSITION
11/04/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/03/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/02/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
24/02/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/09/2022
GNFR
FINAL REFUSAL E-MAILED
01/09/2022
CNFR
FINAL REFUSAL WRITTEN
01/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/07/2022
RFNT
REFUSAL PROCESSED BY IB
28/06/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/06/2022
RFRR
REFUSAL PROCESSED BY MPU
08/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/05/2022
CNRT
NON-FINAL ACTION WRITTEN
04/05/2022
DOCK
ASSIGNED TO EXAMINER
28/04/2022
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
02/02/2022
ALIE
ASSIGNED TO LIE
01/02/2022
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
28/01/2022
MAFR
APPLICATION FILING RECEIPT MAILED
22/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/12/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/12/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RIKEN-NKT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.